XBIT - XBiotech: Several Shots On Goal In Big Target Market Indications
2024-05-24 16:08:27 ET
Summary
- XBiotech Inc.'s Hutrukin is being advanced in a phase 1 study to treat reperfusion injury in patients with ischemic stroke.
- Other studies being deployed are Natrunix for the treatment of patients with pancreatic cancer and rheumatoid arthritis.
- While other biologics have targeted IL-1, none have been established to specifically target IL-1a.
- The True Human "Antibody" technology platform is versatile, in that it can be used to target a wide range of disorders like cancer, stroke, heart attack, arthritis and much more.
XBiotech Inc. ( XBIT ) has been able to complete recruitment for a few studies already, and it has initiated another one targeting patients with Rheumatoid arthritis [RA]. Natrunix is being developed to treat patients with RA and pancreatic cancer. Hutrukin is being advanced to help patients with stroke....
XBiotech: Several Shots On Goal In Big Target Market Indications